Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Equillium, Inc. - Common Stock (NQ:EQ)

0.4725 +0.0351 (+8.02%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Equillium, Inc. - Common Stock

< Previous 1 2 3 4 Next >
EQ Stock Alert: Halper Sadeh LLP is Investigating Whether the Merger of Equillium, Inc. is Fair to Shareholders
From Halper Sadeh LLP
Via Business Wire
Equillium to Acquire Metacrine in All-Stock Transaction
From Equillium, Inc.
Via Business Wire
Equillium to Present at Two Upcoming Investor Conferences
From Equillium, Inc.
Via Business Wire
Equillium Reports Second Quarter 2022 Financial Results and Provides Clinical Development Updates
From Equillium, Inc.
Via Business Wire
Equillium Announces Presentation at the 3rd Annual Cytokine-Based Drug Development Summit
From Equillium, Inc.
Via Business Wire
Equillium to Present at Two Upcoming Investor Conferences
From Equillium, Inc.
Via Business Wire
Equillium Reports First Quarter 2022 Financial Results and Provides Corporate and Clinical Development Updates
From Equillium, Inc.
Via Business Wire
Equillium Announces Publication of Abstract for the Annual Congress of the European Hematology Association
From Equillium, Inc.
Via Business Wire
Equillium Announces Three Poster Presentations at the Annual Meeting of The American Association of Immunologists
From Equillium, Inc.
Via Business Wire
Equillium Announces Three Poster Presentations at the Transplantation & Cellular Meetings of the ASTCT and CIBMTR
From Equillium, Inc.
Via Business Wire
Equillium Announces Oral Presentation at the Italian Society of Experimental Hematology
From Equillium, Inc.
Via Business Wire
Equillium Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate & Clinical Development Updates
From Equillium, Inc.
Via Business Wire
Equillium Announces Two Oral Presentations at the Annual Meeting of the European Society for Blood and Marrow Transplantation
From Equillium, Inc.
Via Business Wire
Equillium Acquires Bioniz Therapeutics Significantly Expanding Pipeline of Novel Immunomodulatory Drug Candidates
From Equillium, Inc.
Via Business Wire
Equillium Provides Timing Update on Conference Presentations
From Equillium, Inc.
Via Business Wire
Equillium to Present at the SVB Leerink Virtual Global Healthcare Conference
From Equillium, Inc.
Via Business Wire
Equillium Announces Multiple Abstracts Accepted for Presentation at the Transplantation & Cellular Meetings of ASTCT and CIBMTR
From Equillium, Inc.
Via Business Wire
Equillium to Present at the H.C. Wainwright Virtual BioConnect Conference
From Equillium, Inc.
Via Business Wire
Equillium Announces Publication of Data in the Journal of Clinical Investigation Highlighting the Importance of the CD6-ALCAM Pathway in the Pathogenesis of Lupus Nephritis
From Equillium, Inc.
Via Business Wire
Equillium Announces Data from Phase 1b EQUIP Study in Patients with Uncontrolled Asthma
From Equillium, Inc.
Via Business Wire
Equillium Announces Additional Patient Data at ASH 2021 Demonstrating Continued Positive and Durable Clinical Responses in Acute Graft-Versus-Host Disease Patients Treated with Itolizumab
From Equillium, Inc.
Via Business Wire
Equillium Reports Third Quarter 2021 Financial Results and Provides Clinical Development Updates
From Equillium, Inc.
Via Business Wire
Equillium to Present at Two Upcoming Investor Conferences
From Equillium, Inc.
Via Business Wire
Equillium Presents Clinical Data from EQUALISE Phase 1b Study in Lupus Patients at the American Society of Nephrology Annual Meeting
From Equillium, Inc.
Via Business Wire
Equillium Presents Interim Safety Data from First Cohort of Asthma Patients in Phase 1b EQUIP Study at the American College of Allergy, Asthma & Immunology Meeting
From Equillium, Inc.
Via Business Wire
Equillium Announces Two Abstracts Accepted for Presentation at the 63rd ASH Annual Meeting and Exposition
From Equillium, Inc.
Via Business Wire
Equillium Announces Interim Safety Data and Reduction in Proteinuria for Lupus Patients Treated with Itolizumab in the EQUALISE Study Presented at the ACR Annual Meeting
From Equillium, Inc.
Via Business Wire
Equillium Announces Two Abstracts Accepted for Presentation at the Upcoming Virtual 2021 American Society of Nephrology Annual Meeting
From Equillium, Inc.
Via Business Wire
Equillium Announces Multiple Abstracts Accepted for Presentation at ACR Convergence 2021
From Equillium, Inc.
Via Business Wire
Equillium to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference
From Equillium, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.